Treatment of heparin-induced thrombocytopenia

Annals of Pharmacotherapy

Volumn 36, Issue 3, 2002, Pages 489-503

  Dager, William E ^a,b,c   White, Richard H ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antithrombins; Argatroban; Bivalirudin; Danaparoid; Fondaparinux; Heparin induced thrombocytopenia; Lepirudin; Melagatran

Indexed keywords

ANCROD; ANTITHROMBIN; ARGATROBAN; DANAPAROID; DESULFATOHIRUDIN; DEXTRAN; DRUG METABOLITE; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; IMMUNOGLOBULIN G; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PROSTACYCLIN; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG CROSS REACTIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOPATHOLOGY; LABORATORY TEST; LIBRARY; META ANALYSIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; CHONDROITIN SULFATES; CLINICAL TRIALS; CORONARY DISEASE; DERMATAN SULFATE; DRUG COMBINATIONS; FEMALE; HEPARIN; HEPARITIN SULFATE; HIRUDIN THERAPY; HIRUDINS; HUMANS; PIPECOLIC ACIDS; PREGNANCY; RABBITS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 0036195475     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A204     Document Type: Review

References (101)

1. Newer strategies for the treatment of heparin-induced thrombocytopenia
2. A 14-year study of heparin-induced thrombo-cytopenia
3. Heparin and platelets
4. Temporal aspects of heparin-induced throm-bocytopenia
5. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
6. Heparin induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
7. Cross-reactivity study of low molecular weight heparin in heparin induced thrombocytopenia
8. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia
9. Impact of the patient population on the risk for heparin-induced thrombocytopenia
10. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies
11. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
12. Heparin induced thrombocytopenia. Diagnosis and contemporary antithrombin management
13. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia
14. Clinical presentation of heparin-induced thrombocytopenia
15. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia
16. Acute systemic reactions to intravenous bolus heparin therapy: Characterization and relationships to heparin-induced thrombocytopenia
17. Failure of early heparin cessation as treatment for heparin-induced thrombo-cytopenia
18. Heparin-induced thrombocytopenia: Patient profiles and clinical manifestations
19. Heparin-induced thrombocytopenia
20. Heparin-induced skin lesions
21. Transient global amnesia associated with acute heparin-induced thrombocytopenia
22. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy
23. Laboratory testing for heparin-induced thrombocytopenia
24. Danaparoid in the prevention of thromboembolic complications
25. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced-thrombocytopenia
26. New treatment options for heparin-induced thrombocytopenia
27. Danaparoid: A review of its pharmacology and clinical use in the management of heparin-induced throm-bocytopenia
28. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
29. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice of thromboplastin used
30. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin
31. Coagulation laboratory testing in patients treated with argatroban
32. Anti-hirudin antibodies induced by recombinant hirudin in the treatment of heparin-induced thrombocytopenia (HIT)
33. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin
34. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia; a prospective study
35. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
36. Heparin-induced thrombocytopenia with thromboembolic complications: Metaanalysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
37. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - Assessment of the whole blood ecarin clotting time
38. A multicenter dose-ranging study of subcutaneous recombinant hirudin in the treatment of deep vein thrombosis
39. Pharmacological properties of hirudin and its derivatives: Potential advantage over heparin
40. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin
41. A comparison of hirudin with heparin in the prevention of restenosis and coronary angioplasty
42. Kinetic mechanism for the interaction of hirulog with thrombin
43. Clinical outcomes of bivalirudin for ischemic heart disease
44. Randomized, double-blind comparison of Hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)
45. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans
46. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin
47. Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery
48. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators
49. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty in unstable or post infarction angina
50. The direct thrombin inhibitor melagatran and its oral prodrug H376/95: Intestinal absorption, properties, biochemical and pharmacodynamic effects
51. Specific factor Xa inhibitors
52. New anticoagulants
53. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibiodies
54. Pentasaccharide Org31540/SR90107A clinical trials update: Less for practice
55. Efficacy of a synthetic pentasaccharide, a pure Xa inhibitor, as an antithrombic agent - A pilot study in the setting of coronary angioplasty
56. The pathogenesis of venous limb gangrene complicating heparin-induced thrombocytopenia
57. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia
58. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT
59. Heparin-induced thrombocytopenia: Towards consensus
60. Anticoagulation with rhirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient
61. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin
62. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients
63. Management of patients with heparin-induced thrombocytopenia: Focus on recombinant hirudin
64. Recombinant hirudin (lepuridin) as anticoagulant in intensive care patients treated with continuous hemodialysis
65. Lepirudin dosing in dialysis dependent renal failure
66. Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis
67. The use of bivalirudin in patients with renal impairment
68. Danaparoid for the treatment of heparin-induced thrombocytopenia
69. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications
70. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
71. Hirudin is not detectable in human breast milk
72. Management of heparin associated thrombocytopenia in pregnancy with subcutaneous r-hirudin
73. Pregnancy complicated by heparin associated thrombocytopenia: Management by a prospectively in vitro selected heparanoid (Org 10172)
74. Anticoagulation of pregnant women with mechanical heart valves. A systematic review of the literature
75. Successful treatment of heparin-induced thrombocytopenia (HIT) type II in childhood with recombinant hirudin
76. Heparin-induced thrombocytopenia in paediatric patients - A review of the literature and a new case treated with danaparoid sodium
77. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation
78. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced throm-bocytopenia type II using anticoagulation with recombinant hirudin
79. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia II: A 1-year experience with 57 patients
80. Hirudin as anticoagulant for cardiopulmonary bypass: Importance of preoperative renal function
81. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban
82. Heparin-induced thrombocytopenia in coronary bypass surgery
83. Perspectives on the long term management of heparin-induced thrombocytopenia
84. Comparison of the effects of two doses of recombinant hirudin compared to heparin in patients with acute myocardial inschemia without ST elevation
85. Effects of recombinant hirudin (lepirudin) compared to heparin in death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST: A randomised trial
86. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndrome
87. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina
88. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
89. Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HITSK). Interim results
90. Safety observations from the pilot phase of the randomized rhirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
91. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial Infarction with Novastatin and TPA (MINT) study
92. Recombinant hirudin (lepirudin) for the improvement of thrombosis with streptokinase in patients with acute myocardial infarction: Results of the HIT-4 trial
93. Hirudin in acute myocardial infarction
94. Randomized, double-blinded comparison of Himlog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction
95. Relation between abrupt vessel closure and the anticoagulation response to heparin or bivalirudin during coronary angioplasty
96. Thrombin-specific anticoagulation with bivalrudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial